News & Events about Newlink Genetics Corporation.
Globe Newswire
3 months ago
Webinar to Review Data Demonstrating Potential Drug Effect and Durable Response Webinar to be held Today June 21, 2023 at 11:00 AM Eastern Time AUSTIN, Texas, June 21, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for ...
Globe Newswire
5 months ago
Oral Presentation on Growth Response to LUM-201 Treatment from OraGrowtH210 Trial Interim Data from OraGrowtH212 Trial Highlighted in Poster Presentation AUSTIN, Texas, April 27, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic ...
Globe Newswire
5 months ago
AUSTIN, Texas, April 19, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2 clinical trials, announced it will report its first quarter 2023 financial results ...
Globe Newswire
8 months ago
12th Annual Corporate Access Event
Register for in-person meetings with Lumos Pharma
AUSTIN, Texas, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc.(NASDAQ:LUMO), a biopharmaceutical company advancing an oral therapeutic candidate for Pediatric Growth Hormone Deficiency (PGHD) through Phase 2...
Globe Newswire
9 months ago
AUSTIN, Texas, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on rare disorders, hosted two key opinion leaders (KOLs) in the field of pediatric endocrinology on December 6th to review the Companys interim data from two Phase 2 ...